Corcept Therapeutics Incorporated logo
Corcept Therapeutics Incorporated CORT
$ 34.17 -4.26%

Annual report 2025
added 02-24-2026

report update icon

Corcept Therapeutics Incorporated Financial Statements 2011-2026 | CORT

Annual Financial Statements Corcept Therapeutics Incorporated

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

3.75 B 6.55 B 2.54 B 2.23 B 2.29 B 3.02 B 1.49 B 1.35 B 2.69 B 818 M 390 M 294 M 372 M 193 M 283 M

Shares

104 M 103 M 104 M 107 M 116 M 115 M 114 M 115 M 114 M 111 M 107 M 101 M 99.8 M 93 M 83.3 M

Historical Prices

36.1 63.4 24.6 20.9 19.8 26.2 12.1 13.4 18.1 7.26 4.98 3 3.21 1.43 3.42

Net Income

99.7 M 141 M 106 M 101 M 113 M 106 M 94.2 M 75.4 M 129 M 8.14 M -6.41 M -31.4 M -46 M -38 M -32.4 M

Revenue

761 M 675 M 482 M 402 M 366 M 354 M 306 M 251 M 159 M 81.3 M 50.3 M 26.6 M 10.4 M 3.31 M -

Cost of Revenue

13 M 10.9 M 6.48 M 5.38 M 5.28 M 5.58 M 5.5 M 5.22 M 3.55 M 2.06 M 1.36 M 882 K 143 K 91 K -

Gross Profit

- - - - - - 301 M 246 M 156 M 79.3 M 48.9 M 25.7 M 10.2 M 3.22 M -

Operating Income

44.8 M 137 M 107 M 113 M 124 M 128 M 112 M 89.5 M 52.9 M 10.2 M -3.44 M -27.6 M -41.5 M -36.3 M -32.3 M

EBITDA

45.9 M 138 M 108 M 114 M 126 M 129 M 114 M 89.7 M 53 M 10.3 M -3.29 M -27.5 M -41.4 M -36.2 M -32.3 M

Operating Expenses

- - - - - - 189 M 157 M 103 M 69.1 M 52.4 M 53.3 M 51.7 M 39.5 M 32.3 M

General and Administrative Expenses

449 M 280 M 184 M 153 M 122 M 105 M - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Corcept Therapeutics Incorporated

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

104 M 104 M 104 M 103 M 103 M 103 M 102 M 102 M 108 M - 107 M 106 M 106 M 106 M 116 M 116 M 117 M 117 M 116 M 115 M 115 M 115 M 114 M 114 M 115 M 115 M 116 M 115 M 115 M 115 M 114 M 113 M 113 M 113 M 111 M 110 M 110 M 110 M 108 M 108 M 102 M 101 M 101 M 101 M 101 M 99.8 M 99.8 M 99.8 M 99.8 M 99.8 M 99.1 M 88.6 M 84.4 M 84.2 M 84.2 M 84 M -

Net Income

19.7 M 35.1 M 20.5 M 47.2 M 35.5 M 27.8 M 31.4 M 27.5 M 15.9 M - 34.6 M 27.4 M 22.8 M - 30.5 M 26.5 M 23.5 M 26 M 21.6 M 28.3 M 30.1 M 29.4 M 26.3 M 20.2 M 18.3 M 22 M 17.7 M 18.2 M 17.5 M 98.3 M 13.8 M 12.6 M 4.39 M 4.6 M 2.58 M 977 K -19 K 959 K -601 K -1.94 M -4.83 M -3.9 M -6.01 M -7.55 M -13.9 M -11.1 M -10.9 M -11.9 M -12.1 M -11.1 M -8.29 M -7.6 M -11 M -9.94 M -6.44 M -8.88 M -7.1 M

Revenue

208 M 194 M 157 M 183 M 164 M 147 M 124 M 118 M 106 M - 102 M 103 M 93.7 M - 96.1 M 91.6 M 79.4 M 85.7 M 86.3 M 88.6 M 93.2 M 87.9 M 81.5 M 72.3 M 64.8 M 66.8 M 64.4 M 62.3 M 57.7 M 53.3 M 42.8 M 35.6 M 27.6 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

4.6 M 3.43 M 2.4 M 2.87 M 2.52 M 2.54 M 1.64 M 1.57 M 1.39 M - 1.34 M 1.32 M 1.25 M - 1.28 M 1.38 M 1.27 M - 1.22 M 1.23 M 1.88 M - 1.45 M 1.38 M 1.24 M - 1.31 M 1.15 M 1.17 M - 976 K 775 K - - - - - - 256 K 439 K 302 K - 235 K 215 K 174 K - 40 K 23 K 20 K - 24 K 48 K - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - 84.5 M 85.1 M 87.3 M 91.4 M 86.5 M 80.1 M 70.9 M 63.6 M 65.3 M 63.1 M 61.2 M 56.5 M 52.1 M 41.8 M 34.8 M 27 M 23.2 M 21.1 M 19.3 M 15.7 M 14.6 M 13 M 11.5 M 9.8 M 8.76 M 7.05 M 5.64 M 4.23 M 4.06 M 2.59 M 1.87 M 1.7 M 1.36 M 1.03 M 827 K - - - - -

Operating Income

10.2 M 26.7 M 3.42 M 46.6 M 35.6 M 29.5 M 31.2 M 29.6 M 14.9 M - 31.9 M 31.4 M 26.8 M - 36.2 M 31.9 M 19.6 M - 24.7 M 35.3 M 37.7 M - 33 M 24.6 M 19 M - 23 M 20.6 M 21 M - 13.6 M 12.8 M 4.74 M - 3.07 M 1.51 M 592 K - 102 K -1.17 M -4.03 M - -5.1 M -6.58 M -12.9 M - -9.74 M -10.8 M -10.9 M - -7.67 M -7.59 M -11 M - -6.44 M -8.87 M -7.1 M

EBITDA

- - 3.7 M - - 29.6 M - - 15 M - 32.5 M 31.4 M 27.1 M - 37 M 31.9 M 19.9 M - 25.2 M 35.6 M 37.9 M - 33.5 M 24.9 M 19.1 M - 23.1 M 20.7 M 21 M - 13.7 M 12.8 M 4.75 M - 3.14 M 1.56 M 619 K - 229 K -1.07 M -3.99 M - -5 M -6.52 M -12.8 M - -9.69 M -10.8 M -10.9 M - -7.66 M -7.58 M -11 M - -6.44 M -8.87 M -7.1 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 13.2 M 13.1 M 14.1 M - 12.4 M 12.4 M 17.3 M - 12.4 M 12.7 M 12.7 M - 8.73 M 8.47 M 11 M - 6.44 M 8.87 M 7.1 M

General and Administrative Expenses

124 M 104 M 90.7 M 73.7 M 66.9 M 56.3 M 45.3 M 43.3 M 48.6 M - 35.2 M 37.8 M 37.5 M - 30.5 M 30 M 29.5 M - 26.5 M 25.6 M 27.5 M - 24.2 M 24.6 M 24.4 M - 21.3 M 20 M 18.4 M - 16.5 M 14.1 M 15 M - 10.9 M 12.1 M 10.4 M - 9.29 M 9.34 M 9.45 M - 9.1 M 7.96 M 9.8 M - 7.18 M 8.16 M 8.38 M - 5.69 M 5.75 M 7.49 M - 3.21 M 2.67 M 2.17 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Corcept Therapeutics Incorporated CORT
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Corcept Therapeutics Incorporated plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
NextCure NextCure
NXTC
$ 12.67 0.52 % $ 354 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Liquidia Corporation Liquidia Corporation
LQDA
$ 34.25 -0.38 % $ 2.23 B usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 5.02 6.13 % $ 214 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.58 -1.38 % $ 1.07 B canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
ADMA Biologics ADMA Biologics
ADMA
$ 15.57 -5.89 % $ 3.71 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 -0.73 % $ 4.47 M chinaChina
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.19 -1.18 % $ 208 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 75.6 -1.22 % $ 1.46 B usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.24 1.91 % $ 2.55 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.5 -8.28 % $ 383 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 159.87 -2.57 % $ 7.95 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 65.73 -1.22 % $ 12.6 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.72 -3.31 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.54 0.18 % $ 11.6 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.26 -1.31 % $ 1.36 B britainBritain
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Codexis Codexis
CDXS
$ 1.25 16.2 % $ 91.8 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.2 -6.71 % $ 3.74 M usaUSA